DENTSPLY SIRONA Inc. (XRAY) stock intrinsic value fair value estimate & owner earnings analysis

Dentsply Sirona is the world's largest maker of professional dental products: CEREC and Primescan CAD/CAM scanning and milling systems, imaging and treatment-center equipment (Connected Technology Solutions, $1.04 billion of 2025 sales), consumables such as endodontic files, restoratives and preventive products (Essential Dental Solutions, $1.47 billion), implants and clear aligners (Orthodontic and Implant Solutions, $850 million) and the Wellspect urology business ($325 million). Total 2025 sales were $3.68 billion, down from $4.23 billion in 2021. What the business earns. We measure the cash the business produces for its owners: operating cash flow with short-term swings in receivables, inventory and payables stripped out, less the cost of stock paid to employees and the capital spending needed to keep the business as it is. On that basis owner earnings per share were $2.16 in 2016, $2.46 in 2017, $1.47 in 2018, $2.07 in 2019, $1.44 in 2020, $2.84 in 2021, $1.80 in 2022, $1.13 in 2023, $0.72 in 2024 and $1.47 in 2025. Reported 2025 cash flow ($235 million) looks far worse than the business actually earned, because about $222 million went into higher receivables, inventory and lower accrued liabilities; 2024 was the reverse, flattered by a $95 million release. Removing those swings gives a steadier picture. Large non-cash charges are added back: $1.96 billion of goodwill and intangible write-offs over 2023-2025 and about $211 million a year of amortization of acquired intangibles. Those write-offs record that past acquisitions (Sirona, Byte and others) did not earn back their cost; that history of capital destruction is carried in our cases, not in the earnings level. Because the company borrows heavily, we value the business before its lenders and then subtract what it owes. Adding back interest paid, the business produced roughly $689 million in 2021, $457 million in 2022, $337 million in 2023, $238 million in 2024 and $359 million in 2025. We anchor on about $345 million, the middle of 2022-2025. Earlier years describe a larger business that still had Byte aligners and stronger CAD/CAM and implant volumes, so we do not use them. The most recent year's growth (2024 to 2025) was strongly positive, but only because 2024 was depressed; we assume no growth in the near term. The first half of 2026 still showed sales down about 2% (second quarter down about 4%), though operating cash flow improved to $139 million from $55 million. Base case: sales keep sliding for about three more years. CAD/CAM volume losses to cheaper scanner competitors, weak premium implants in the United States and the end of Byte continue, so business cash flow falls 3%, 2% and 1% in 2026-2028 and then holds flat. About $30 million a year of cash restructuring costs under the 2026 Plan ($55-65 million in total) is charged in 2026 and 2027. The plan's targeted $120 million of annual savings is not credited here, because management intends to reinvest part of it and the company has not yet shown it can turn savings into lasting earnings. After year ten the stream fades 1% a year: the installed base of equipment and the consumables franchise keep earning, but the record is one of slow share loss. The business is worth about $4.9 billion; less net debt of about $2.0 billion leaves about $14.50 a share. Bear case: the erosion of 2021-2024 continues at about 4% a year, and one dental downturn lands on top of it. Dental equipment and elective procedures are cyclical. In the 2020 shutdown this company's sales fell 17% and business cash flow fell about 27% from 2019, so we cut cash flow 30% in two years and 15% in a third. Business cash flow bottoms near $205 million, still about twice the roughly $90 million annual interest bill, so the debt can be carried. In that downturn, covenants that step down from 4.25 times EBITDA in late 2025 to 2.5 times by the end of 2027 would likely force costly refinancing or asset sales, which we charge as about $250 million of extra debt cost. The business is worth about $3.1 billion against about $2.25 billion owed, leaving about $4.13 a share. Bull case: the 2026 Plan delivers most of its $120 million of savings net of reinvestment, sales stabilize at today's level, and business cash flow rises to about $415 million by 2028 and then holds. That is roughly the 2022 level, so it is a return to something the company has already earned rather than new growth. The business is worth about $6.8 billion; less $2.0 billion of net debt leaves about $23.84 a share. We give no credit to a return to revenue growth, which would depend on winning back share. Debt. At December 31, 2025 the company owed about $2.33 billion: $750 million of 3.3% senior notes due 2030, about $800 million of low-rate euro, Swiss franc and yen private placement notes maturing 2026-2031, $550 million of 8.375% junior subordinated notes due 2055 issued in June 2025, plus commercial paper and the current portion. It held $326 million of cash, so net debt was about $2.0 billion; at June 30, 2026 it was similar. The cheap European private placements save money until they mature, and the costly junior notes cost more than ordinary debt. We judge that these roughly offset, and we make no further adjustment. In December 2025 lenders loosened the leverage covenants and added limits on payments to shareholders, and in February 2026 the board eliminated the dividend. What could make this wrong: competitive pricing in scanners and implants could prove permanent and steeper than assumed; the turnaround could fail with covenant pressure arriving before the savings; or, on the upside, the new endodontic and imaging products and the 2026 savings could stabilize sales sooner than we assume. Our earlier published estimates were made on a different basis and are not comparable to these figures. Margin-of-safety price. We are only moderately sure of the earnings level. Business cash flow has ranged from $238 million to $689 million in five years and is still drifting down, though 2025 and the first half of 2026 suggest the underlying run rate is closer to $340-360 million than to the 2024 low. The worst plausible outcome is a dental downturn arriving while the covenants are tightening: with shareholders owning only the slice above $2 billion of debt, a 25-30% fall in cash flow would wipe out most of the equity, as the bear case shows. The business has no single-customer dependence, its consumables and the installed equipment base are hard to displace quickly, and its maturities are spread out, so it would likely survive, but shareholders could be heavily diluted. If we are wrong that the decline flattens and it simply continues at 4% a year with no recession, the shares are worth about $6.50. If we are wrong about the downturn too, they are worth about $4. The company now pays no dividend, so any return in the cases must come from the business recovering its value, which we would expect to take three to five years. For the median outcome to imply 20% a year over about five years, with little downside if the decline simply continues, the margin-of-safety price is $5.50 a share.